Body composition in patients with schizophrenia: Comparison with healthy controls by unknown
Sugawara et al. Annals of General Psychiatry 2012, 11:11
http://www.annals-general-psychiatry.com/content/11/1/11PRIMARY RESEARCH Open AccessBody composition in patients with schizophrenia:
Comparison with healthy controls
Norio Sugawara1*, Norio Yasui-Furukori1, Shoko Tsuchimine1, Akira Fujii1, Yasushi Sato1,3, Manabu Saito1,
Masashi Matsuzaka2, Ippei Takahashi2 and Sunao Kaneko1Abstract
Background: Recently, a relationship between obesity and schizophrenia has been reported. Although fat- mass
and fat free mass have been shown to be more predictive of health risk than body mass index, there are limited
findings about body composition among patients suffering from schizophrenia. The aim of this study is to compare
the body composition of schizophrenia patients with that of healthy subjects in Japan.
Methods: We recruited patients (n = 204), aged 41.3 ± 13.8 (mean ± SD) years old with the DSM-IV diagnosis of
schizophrenia who were admitted to psychiatric hospital using a cross-sectional design. Subjects' anthropometric
measurements including weight, height, body mass index (BMI), and medications were also collected. Body fat,
percent (%) body fat, fat- free mass, muscle mass, and body water were measured using the bioelectrical
impedance analysis (BIA) method. Comparative analysis was performed with schizophrenic subjects and 204 healthy
control individuals.
Results: In a multiple regression model with age, body mass index, and dose in chlorpromazine equivalents,
schizophrenia was a significantly linked with more body fat, higher % body fat, lower fat- free mass, lower muscle
mass, and lower body water among males. In females, schizophrenia had a significant association with lower %
body fat, higher fat- free mass, higher muscle mass, and higher body water.
Conclusions: Our data demonstrate gender differences with regard to changes in body composition in association
with schizophrenia. These results indicate that intervention programs designed to fight obesity among
schizophrenic patients should be individualized according to gender.
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The prevalence of obesity among patients with schizo-
phrenia is higher than the general population [1,2].
Obesity among patients with schizophrenia is a growing
concern because being overweight is a major risk factor
for metabolic syndrome, cardiovascular diseases, and pre-
mature death, and this risk is nearly double that of the
general population [3–5]. In addition, in people with
schizophrenia, obesity is associated with lower self-esteem,
poorer psychosocial adaptation [6], reduced quality of life
[7], non-compliance with antipsychotic medication regime
[8] and increased medication cost [9].* Correspondence: nsuga3@yahoo.co.jp
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reproduction in any medium, provided the origIn previous studies that have considered obesity in
patients with schizophrenia, weight or body mass index
(BMI) was commonly used as measurement parameters.
However, it is important to consider body composition
in detail because the excess accumulation of body fat, ra-
ther than BMI, causes the health risks associated with
obesity [10]. Although BMI correlates highly with fat
mass, depending on the level of muscularity, this value
can be misleading regarding the level of adiposity of an
individual.
Recently, a bioelectrical impedance analysis (BIA) method
was developed that can measure body composition vari-
ables. BIA is based on the principle that there is less resis-
tance to an alternating current passing through tissues that
contain fluids and electrolytes than those containing rela-
tively high amounts of lipids [11]. BIA results correlate wellal Ltd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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[12,13]. BIA is a relatively quick procedure that is inexpen-
sive and suitable for examining large numbers of people for
studies.
The objectives of this study were to use BIA to compare
the body composition variables between patients with
schizophrenia and healthy individuals. To our knowledge,




This study was conducted between July 2010 and No-
vember 2010. The subjects were 204 outpatients (74
males and 130 females) at Hirosaki University Hospital
in Japan who were diagnosed with either schizophrenia
or schizoaffective disorder based on the DSM-IV diagnos-
tic criteria. The diagnoses of the patients were recorded
from their medical charts. As a reference group, 204
healthy volunteers (74 males and 130 females) were also
included. The data collection for this study was approved
by the Ethics Committee of the Hirosaki University School
of Medicine and all subjects provided written informed
consent before participating in this study.
Procedure
Information on the subjects’ demographic data (age
and sex), and current medications was obtained from
their medical records. In order to have comparable
value for each patient, medication was converted to
chlorpromazine equivalents [14]. Patient heights were
determined without shoes on a portable stadiometer
with the mandible plane parallel to the floor. Body
composition was measured using the Tanita MC-190
body composition analyzer [15] with correction for
light indoor clothing. The measurement procedure
required the subject to stand barefooted on the analyzer
and to hold a pair of handgrips, one in each hand. The
device uses multiple-frequency (5 kHz, 50 kHz,
250 kHz, and 500 kHz) BIA technology and has 8 tactile
electrodes: 2 are in contact with the palm and thumb of
each hand, and 2 are in contact with the anterior and pos-
terior aspect of the sole of each foot. To calculate body
fat, percent (%) body fat, fat- free mass, muscle mass, andTable 1 Demographic characteristics of patients with schizop
Male
Schizophrenia Control p
Age (years old) 39.0±13.5 40.8±11.8 p
Height (cm) 165.5±8.6 170.8±6.5 p
Body weight (kg) 69.2±16.5 68.5±10.7 p
BMI (kg/m2) 25.2±5.5 23.4±3.2 pbody water for the entire body, the MC-190 uses a propri-
etary equation developed by the manufacturer.Statistical analysis
Descriptive statistical analyses were performed to de-
scribe the demographic and clinical variables. To com-
pare the main demographic and clinical characteristics
between patients and control, an unpaired Student’s t-test
was performed to analyze continuous variables. Data are
presented as means ± SD. Multiple linear regression ana-
lysis was employed to analyze the continuous variables of
body composition. Healthy individuals were used as the
reference category. Regression analyses were conducted
in adjusted conditions for confounding factors (age, BMI,
and dose in CP equivalents). A value of p< 0.05 was con-
sidered significant. The data were analyzed using the
PASW Statistics-PC-software for Windows, Version
18.0.0.Results
Demographic characteristics
The characteristics of participant are listed in Table 1.
Among males, height was significantly higher in
healthy individuals than in patients with schizophre-
nia. In females, height and body weight were signifi-
cantly higher in patients with schizophrenia than in
healthy individuals. Body mass index was significantly
higher in patients with schizophrenia than in healthy
individuals among both genders. No differences were
observed for any of the other characteristics.Body composition measurements
Table 2 shows the body composition measurements of
patients with schizophrenia and healthy controls.
Among males, body fat, and % body fat were signifi-
cantly higher in patients with schizophrenia than in
healthy individuals; hence, fat- free mass, muscle mass,
and body water were significantly higher in healthy indi-
viduals than in patients with schizophrenia. In females,
body fat, fat- free mass, muscle mass, and body water
were significantly higher in patients with schizophrenia
than in healthy individuals.hrenia and healthy controls
Female
value Schizophrenia Control p value
=0.398 42.5±13.9 43.4±12.9 p=0.592
<0.001 160.6±7.9 157.6±6.1 p<0.01
=0.767 63.4±13.0 54.8±10.1 p<0.001
<0.05 24.6±5.0 22.1±4.0 p<0.001
Table 2 Body composition measurements of patients with schizophrenia and healthy controls
Male Female
Schizophrenia Control p value Schizophrenia Control p value
Body Fat (kg) 20.2±12.4 13.0±5.8 p<0.001 19.8±9.8 16.3±7.6 p<0.01
% Body Fat 27.7±11.8 18.3±5.8 p<0.001 30.2±9.8 28.5±7.6 p=0.124
Fat Free Mass (kg) 49.0±9.7 55.5±5.9 p<0.001 43.6±7.9 38.5±3.6 p<0.001
Muscle Mass (kg) 46.3±9.2 52.6±5.6 p<0.001 41.2±7.5 36.3±3.3 p<0.001
Body Water (kg) 34.3±6.1 38.4±4.6 p<0.001 31.3±5.2 27.8±3.3 p<0.001
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composition characteristics
The results of the regression analyses examining the
associations between the diagnosis of schizophrenia and
body composition are presented in Table 3. Among
males, schizophrenia was a significantly associated with
higher body fat, higher % body fat, lower fat- free mass,
lower muscle mass, and lower body water. In females,
being schizophrenic had a significant association with
lower % body fat, higher fat free mass, higher muscle
mass, and higher body water.
Discussion
The present study on the body composition of patients
diagnosed with schizophrenia is the largest study of this
nature in an Asian population. Compared to the reference
group, male patients with schizophrenia were found to
have higher % body fat and lower muscle mass. In con-
trast, female patients with schizophrenia did not exhibit
this association.
Other studies [16–18] have compared the body com-
position of patients with schizophrenia and healthy indi-






















Dose in CP equivalents 0.132
Body in CP equivalents 0.118schizophrenia had higher % body fat and lower fat- free
mass than healthy controls. Satoh et al. [17] performed a
study involving 80 male schizophrenic patients and 64
healthy male individuals and showed that patients with
schizophrenia had higher % body fat than healthy con-
trols. Furthermore, Saarni et al. [18] reported that
schizophrenia (n = 58) was significantly associated with a
higher % body fat and lower fat- free mass after adjust-
ing for age, gender, and BMI.
It is now well recognized that adipose tissue, especially
in the abdominal region, is associated with the secretion
of pro-inflammatory (e.g., interleukin- 6, and tumor ne-
crosis factor- alpha) and catabolic (e.g., leptin, and retinol-
binding protein 4) agents [19,20]. These molecules, in
concert with the insulin resistance associated with abdom-
inal obesity, contribute to a loss of muscle mass [19].
The mechanism for increased body fat among males
has not been completely elucidated. However, patients
with schizophrenia are at risk for developing obesity due
to poor dietary habits, lower resting energy expenditure,
lack of exercise or limited activity due to the negative
symptoms of schizophrenia. Previous studies [21,22] have
suggested an increased propensity for storing excess fat asmposition
female
p-value Beta coefficient p-value
p< 0.01 −0.023 p = 0.241
p< 0.001 0.972 p< 0.001
p< 0.001 −0.041 p = 0.105
P = 0.402 −0.041 p = 0.113
p< 0.05 0.100 p< 0.01
p< 0.001 0.867 p< 0.001
p< 0.001 −0.094 p< 0.05
p= 0.097 −0.069 p = 0.108
p= 0.755 −0.238 p< 0.001
p< 0.001 0.322 p< 0.001
p< 0.001 0.194 p< 0.01
p= 0.157 0.149 p< 0.05
p= 0.724 −0.233 p< 0.001
p< 0.001 0.312 p< 0.001
p< 0.001 0.198 p< 0.01
p= 0.155 0.149 p< 0.05
p= 0.192 0.131 p< 0.05
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hypercortisolemia due to abnormalities of the hypothal-
amic- pituitary- adrenal (HPA) axis might also affect the
development of central fat accumulation [23,24].
In contrast with male patients with schizophrenia, we
did not find a higher % body fat or lower muscle mass
among schizophrenic females relative to control females
after multiple regression analysis. Previous studies com-
paring the body composition of patients with schizo-
phrenia and healthy individuals analyzed a mixed subject
pool of both genders or only male subjects. Therefore,
we are reporting for the first time a comparison of the
body composition of female schizophrenia patients and
healthy individuals. One possible explanation for differ-
ences according to gender is that estrogen may affect
the body composition. Animal studies also suggest that
estrogen may play a role in the prevention of obesity
[25]. Ovariectomized animals have increased adiposity
compared with animals with intact ovaries [26]. Estrogen
treatment in ovariectomized animals has been associated
with significantly reduced adipose mass and adipocyte
size. In addition, estrogen has also been shown to protect
the muscle mass by stabilizing the muscle membrane [27].
Another possible explanation is that differences in phys-
ical exercise and socio-environmental factors might affect
the body composition.
The current study also has some limitations. First, it
was a cross-sectional study. It will be necessary to carry
out a follow-up survey to clarify the reason for differ-
ences in the body composition between male patients
and the reference group. We intend to follow-up this co-
hort prospectively in order to assess metabolic changes
during the course of the illness and as a function of anti-
psychotic regimes. Second, patient recruitment was
restricted to outpatients presenting to the hospital for a
review of their health problems. No other population
groups, such as children, adolescents or unmedicated
patients, were included. Third, all possible parameters
were not included in this study such as dietary habits,
physical activity levels, the duration of illness and treat-
ment, schizophrenic symptoms and medications. In par-
ticular, antipsychotic medications may be important
factors. The use of first vs. second generation antipsy-
chotics might also confound the results [28]. A stratified
analysis by according to medication is needed in the fu-
ture study.
Conclusion
This study has shown that the male patients with schizo-
phrenia had more body fat and a lower muscle mass than
healthy individuals. Previous studies [29,30] have suggested
that long-term programs that incorporate nutrition, exer-
cise, and behavioral interventions can prevent weight gain
among schizophrenic patients. The intervention programfor obesity among schizophrenic patients should be pre-
pared individually for each gender.
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